Cure8 research brief
A Cochrane network meta-analysis compares many biologic medicines used for Crohn’s disease, which can help patients and clinicians understand how different drugs and drug classes stack up for inducing and keeping remission.
This summary is written for patients (plain-language) so it’s directly relevant to people deciding about or already on biologic therapy.
Adults with Crohn’s disease considering or taking biologic therapy; clinicians who prescribe biologics; researchers interested in comparative effectiveness of IBD treatments.
This plain-language summary reports on a Cochrane network meta-analysis that pooled and compared many biologic therapies used to induce and maintain remission in Crohn’s disease. It focuses on relative benefits and harms across drugs and classes rather than on one brand or study.
The content is a translation of the Cochrane PLS; it is intended to help patients and clinicians understand the review’s conclusions without technical detail. For clinical decisions, readers should consult the full Cochrane review and discuss options with their care team.
The PLS format means findings are summarized for accessibility; it does not replace individualized medical advice.
This item is the plain-language summary (Russian translation) of a Cochrane systematic review and network meta-analysis (2026). The PLS summarizes pooled evidence but is not a full technical report; consult the full Cochrane review for detailed methods, certainty ratings, and numeric results.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
A broad comparison of many maintenance therapies helps patients and clinicians understand which drugs have trial evidence for preventing relapse or loss of response in Crohn's disease. The review highlights adalimumab,...
People with IBD and their clinicians want ways to predict which advanced therapy will work best. This review summarizes current evidence and shows that, despite many studies, no biomarker is reliably ready for routine...
Sarcopenia or low muscle mass may be linked with worse endoscopic healing and reduced durability of biologic therapy in IBD, particularly Crohn's disease, which could matter for prognosis and treatment planning if...
